









Markets
/
Stocks
/
nasdaq-rxst
/

Rxsight Inc

RXST

8.390USD

+0.570+7.29%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

344.67MMarket Cap

LossP/E TTM



Rxsight Inc

8.390

+0.570+7.29%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rxsight Inc

Currency: USD Updated: 2026-02-06

Key Insights

Rxsight Inc's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 85 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 10.39.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rxsight Inc's Score

Industry at a Glance

Industry Ranking

85 / 205

Overall Ranking

233 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Rxsight Inc Highlights

StrengthsRisks

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 185.54% year-on-year.

Overvalued

The company’s latest PE is -9.57, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 34.25M shares, decreasing 29.81% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 693.15K shares of this stock.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

10.389

Target Price

+32.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Rxsight Inc is 7.17, ranking 98 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 30.34M, representing a year-over-year decrease of 14.09%, while its net profit experienced a year-over-year decrease of 54.88%.

Score

Industry at a Glance

Previous score

7.17

Change



Financials

8.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.62

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rxsight Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Rxsight Inc is 7.75, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -9.57, which is -44.33% below the recent high of -5.33 and -606.09% above the recent low of -67.56.

Score

Industry at a Glance

Previous score

7.75

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 85/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Rxsight Inc is 5.82, ranking 182 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 10.00, with a high of 14.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

5.82

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

10.389

Target Price

+32.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Rxsight Inc

RXST

Stryker Corp

SYK

Medtronic PLC

MDT

Dexcom Inc

DXCM

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Rxsight Inc is 6.53, ranking 133 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 10.32 and the support level at 7.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.23

Change

0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.182

Sell

RSI(14)

36.701

Neutral

STOCH(KDJ)(9,3,3)

20.953

Buy

ATR(14)

0.553

High Vlolatility

CCI(14)

-97.175

Neutral

Williams %R

72.690

Sell

TRIX(12,20)

-0.952

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

8.264

Buy

MA10

8.680

Sell

MA20

9.204

Sell

MA50

10.625

Sell

MA100

9.779

Sell

MA200

10.622

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rxsight Inc is 7.00, ranking 80 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 83.29%, representing a quarter-over-quarter decrease of 11.44%. The largest institutional shareholder is The Vanguard, holding a total of 2.23M shares, representing 5.42% of shares outstanding, with 7.59% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.25M

-10.28%

The Vanguard Group, Inc.

Star Investors

2.15M

-5.46%

Millennium Management LLC

2.19M

-16.01%

Artisan Partners Limited Partnership

1.75M

-22.15%

D. E. Shaw & Co., L.P.

1.83M

+38.79%

NO STREET GP LP

1.63M

+35.42%

Two Sigma Investments, LP

1.39M

+123.95%

Citadel Advisors LLC

1.29M

+25.52%

DWS Investments UK Limited

952.53K

-22.01%

BNP Paribas Securities Corp. North America

903.85K

+87.88%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rxsight Inc is 4.61, ranking 102 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Rxsight Inc’s latest ESG disclosure is at an average level in the Healthcare Equipment & Supplies industry, showing no material impact on overall risk.